PFA Pension Forsikringsaktieselskab Acquires New Stake in DexCom, Inc. $DXCM

Key Points

• PFA Pension Forsikringsaktieselskab bought 345,482 DexCom shares in Q4, a stake valued at about $23.17 million and roughly 0.09% of the company per its SEC filing.
• DexCom beat Q1 estimates with non‑GAAP EPS of $0.56 versus $0.47 and revenue of $1.19B (up 15% YoY), but management merely reaffirmed FY26 guidance (~$5.2–$5.3B), producing mixed market reactions and some analyst price‑target trims; consensus rating is "Moderate Buy" with an average target of $83.73.
• Ownership and insider activity: Institutional investors own 97.75% of DexCom, while insiders hold 0.32%; an EVP sold 1,700 shares under a Rule 10b5‑1 plan, modestly reducing his position.

PFA Pension Forsikringsaktieselskab acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 345,482 shares of the medical device company's stock, valued at approximately $23,168,000. PFA Pension Forsikringsaktieselskab owned approximately 0.09% of DexCom as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. boosted its stake in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company's stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new stake in DexCom during the 3rd quarter valued at $29,000. CVA Family Office LLC boosted its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after purchasing an additional 147 shares during the last quarter. ORG Partners LLC boosted its stake in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company's stock valued at $34,000 after purchasing an additional 281 shares during the last quarter. Finally, Spire Wealth Management boosted its stake in DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company's stock valued at $38,000 after purchasing an additional 305 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on DXCM shares. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday. Raymond James Financial set a $81.00 target price on DexCom in a research note on Friday. Wells Fargo & Company cut their target price on DexCom from $93.00 to $85.00 and set an "overweight" rating on the stock in a research note on Friday, February 13th. BTIG Research reiterated a "buy" rating and set a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Finally, Piper Sandler reiterated an "overweight" rating on shares of DexCom in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and an average price target of $83.73.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is currently owned by company insiders.

DexCom Stock Performance

DXCM stock opened at $61.35 on Monday. The company has a market cap of $23.67 billion, a P/E ratio of 26.22, a price-to-earnings-growth ratio of 1.18 and a beta of 1.40. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The stock's fifty day moving average price is $65.87 and its 200-day moving average price is $66.41.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company's revenue for the quarter was up 15.0% on a year-over-year basis. During the same period last year, the business posted $0.32 EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.52 earnings per share for the current year.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; non‑GAAP EPS of $0.56 topped estimates and revenue rose 15% to $1.19B with margins improving — a clear near‑term earnings beat that supports upside. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Company reported record new patient starts globally and cites product momentum plus coverage expansion as drivers — supports sustained top‑line growth and market penetration for its CGM franchise. DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
• Positive Sentiment: Medicare National Coverage Determination (NCD) remains the biggest catalyst for 2026 per RBC — a favorable NCD could materially expand U.S. addressable market and is being watched by investors. DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says
• Neutral Sentiment: Management reaffirmed FY26 revenue guidance (~$5.2–$5.3B) rather than raising it; that keeps the outlook intact but removes an upside surprise for the full year amid geopolitical caution. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Negative Sentiment: Some brokerages trimmed price targets (TD Cowen cut to $75; BTIG lowered its PT to $80) even as they keep Buy ratings — reduces near‑term analyst upside and may cap gains. Benzinga
• Negative Sentiment: Shares saw an after‑hours pullback in some sessions despite the beat as investors parsed the lack of an upgraded FY revenue outlook and geopolitical risk; watch volume and guidance commentary in the call transcript/slides. Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.